Development and therapeutic applications of nitric oxide releasing materials to treat erectile dysfunction

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The role of nitric oxide (NO) in erectile physiology is well documented. NO activates relaxation of corporal cavernosal smooth muscle tissue resulting in increased blood flow into the penis resulting in an erection. At present, pharmacologic treatments for erectile dysfunction, such as the phosphodiesterase-5 inhibitors, potentiate the erectile response generated by NO. However, a new class of treatments at a preclinical stage may allow localized delivery of NO to the penis via cutaneous application. These treatments may be of particular value to patients with a neurogenic component to their erectile dysfunction, and may act synergistically with phosphodiesterase-5 inhibitors to increase their efficacy.

Original languageEnglish (US)
Article numberFSO53
JournalFuture Science OA
Volume1
Issue number1
DOIs
StatePublished - Aug 1 2015

Fingerprint

Erectile Dysfunction
Nitric Oxide
Phosphodiesterase 5 Inhibitors
Penis
Therapeutics
Smooth Muscle
Muscles
Skin

Keywords

  • ED
  • erectile dysfunction
  • nanoparticles
  • nitric oxide
  • NO
  • PDE5 inhibitors
  • phosphodiesterase-5 inhibitors

ASJC Scopus subject areas

  • Biotechnology

Cite this

Development and therapeutic applications of nitric oxide releasing materials to treat erectile dysfunction. / Davies, Kelvin.

In: Future Science OA, Vol. 1, No. 1, FSO53, 01.08.2015.

Research output: Contribution to journalArticle

@article{6518fa2fa815423aa31766d0cf182851,
title = "Development and therapeutic applications of nitric oxide releasing materials to treat erectile dysfunction",
abstract = "The role of nitric oxide (NO) in erectile physiology is well documented. NO activates relaxation of corporal cavernosal smooth muscle tissue resulting in increased blood flow into the penis resulting in an erection. At present, pharmacologic treatments for erectile dysfunction, such as the phosphodiesterase-5 inhibitors, potentiate the erectile response generated by NO. However, a new class of treatments at a preclinical stage may allow localized delivery of NO to the penis via cutaneous application. These treatments may be of particular value to patients with a neurogenic component to their erectile dysfunction, and may act synergistically with phosphodiesterase-5 inhibitors to increase their efficacy.",
keywords = "ED, erectile dysfunction, nanoparticles, nitric oxide, NO, PDE5 inhibitors, phosphodiesterase-5 inhibitors",
author = "Kelvin Davies",
year = "2015",
month = "8",
day = "1",
doi = "10.4155/fso.15.53",
language = "English (US)",
volume = "1",
journal = "Future Science OA",
issn = "2056-5623",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Development and therapeutic applications of nitric oxide releasing materials to treat erectile dysfunction

AU - Davies, Kelvin

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The role of nitric oxide (NO) in erectile physiology is well documented. NO activates relaxation of corporal cavernosal smooth muscle tissue resulting in increased blood flow into the penis resulting in an erection. At present, pharmacologic treatments for erectile dysfunction, such as the phosphodiesterase-5 inhibitors, potentiate the erectile response generated by NO. However, a new class of treatments at a preclinical stage may allow localized delivery of NO to the penis via cutaneous application. These treatments may be of particular value to patients with a neurogenic component to their erectile dysfunction, and may act synergistically with phosphodiesterase-5 inhibitors to increase their efficacy.

AB - The role of nitric oxide (NO) in erectile physiology is well documented. NO activates relaxation of corporal cavernosal smooth muscle tissue resulting in increased blood flow into the penis resulting in an erection. At present, pharmacologic treatments for erectile dysfunction, such as the phosphodiesterase-5 inhibitors, potentiate the erectile response generated by NO. However, a new class of treatments at a preclinical stage may allow localized delivery of NO to the penis via cutaneous application. These treatments may be of particular value to patients with a neurogenic component to their erectile dysfunction, and may act synergistically with phosphodiesterase-5 inhibitors to increase their efficacy.

KW - ED

KW - erectile dysfunction

KW - nanoparticles

KW - nitric oxide

KW - NO

KW - PDE5 inhibitors

KW - phosphodiesterase-5 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85019310356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019310356&partnerID=8YFLogxK

U2 - 10.4155/fso.15.53

DO - 10.4155/fso.15.53

M3 - Article

AN - SCOPUS:85019310356

VL - 1

JO - Future Science OA

JF - Future Science OA

SN - 2056-5623

IS - 1

M1 - FSO53

ER -